Gianna Dafflisio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gianna Dafflisio has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Sitaram M. Emani
Boston Children’s Hospital
3 shared publications - Aditya Mahesh
College of Medicine, Pennsylvania State University, University Park, PA 16802, USA
1 shared publication - Ahmed A. Abdelrehim
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
1 shared publication - Alexandra K. Glazier
New England Donor Services; Brown University School of Public Health
1 shared publication - Alok A. Khorana
Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
1 shared publication Alok Vedvyas
New York University Langone Health, New York University Grossman School of Medicine, New York, NY USA
1 shared publication
Latest Publications
- 5 October 2026
- Published by American Physical Society (APS) in Physical Review Letters
- Vol. 137 (15) , 158401
Stochastic Elastohydrodynamics of Soft Valves
A simplified model of the heart's mitral valve shows that flow fluctuations can cause a soft valve to close at about one-tenth the pressure required under steady flow.
- 5 October 2026
- Published by American Physical Society (APS) in Physical Review Letters
- Vol. 137 (15) , 158401
Stochastic Elastohydrodynamics of Soft Valves
A simplified model of the heart's mitral valve shows that flow fluctuations can cause a soft valve to close at about one-tenth the pressure required under steady flow.
- Open Access
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eadw4669
Design and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a spring mechanism
Congenital heart valve defects often require surgical intervention for survival. Now, there are no valve prosthetics on the market that are designed for babies and toddlers who grow rapidly. Recent advancements in expandable valves hold promise for these young patients but currently require invasive balloon catheter procedures for device expansion. Here, we describe the design and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a springlike mechanism imparted by the superelastic properties of nitinol. Studies in piglets demonstrated appropriate constraint of the device to small diameters (8 to 9 millimeters) upon implantation, acute valve function, and the ability of the stent to proportionately expand with growth up to 13 millimeters after 6 weeks without subsequent interventions after implantation. We expect that the growth-adaptive stent concept could be broadly leveraged to eliminate surgeries and invasive procedures as young patients grow.
- 20 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (8) , eadw4669
Open AccessDesign and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a spring mechanism
Congenital heart valve defects often require surgical intervention for survival. Now, there are no valve prosthetics on the market that are designed for babies and toddlers who grow rapidly. Recent advancements in expandable valves hold promise for these young patients but currently require invasive balloon catheter procedures for device expansion. Here, we describe the design and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a springlike mechanism imparted by the superelastic properties of nitinol. Studies in piglets demonstrated appropriate constraint of the device to small diameters (8 to 9 millimeters) upon implantation, acute valve function, and the ability of the stent to proportionately expand with growth up to 13 millimeters after 6 weeks without subsequent interventions after implantation. We expect that the growth-adaptive stent concept could be broadly leveraged to eliminate surgeries and invasive procedures as young patients grow.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 141-150
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change
PURPOSE: As the complexity and need for cancer care services continue to grow, time to treatment initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive analyses identifying the recent changes in TTI and the important variables causing variation in TTI for all the most prevalent cancer types. METHODS: This is a retrospective, observational study using data from the National Cancer Database from 2004 to 2015. The database was queried for newly diagnosed patients with cancer stages I-IV who had TTI within 0-180 days. Stepwise linear regression models were used as a variable selection technique to identify the most significant independent variables to evaluate as predictor variables. RESULTS: The study sample included 5,615,193 patients (median age, 65; 51.5% female; 86.1% White) across 30 different cancer types (most prevalent: breast [22.1%], lung [18.8%], prostate [16.6%]). The median [IQR] TTI across all 30 cancer types was 26 [6-47] days, with an increase of 7 days from 2004 (21 [4-44]) to 2015 (28 [9-49]; P < .001). No individual cancer type decreased in TTI from 2004 to 2015. The proportion of patients diagnosed with new stage I disease increased by 52.2% from 2004 (28.4%, n = 78,732) to 2015 (43.2%, n = 256,150). All other stages decreased in percent incidence. There was a 100.0% increase in median TTI for stage I patients from 2004 to 2015 (14-28 days). Cancer stage was the most important predictor of change in TTI for 16 cancer types ( P < .001 for all 16). CONCLUSION: TTI is increasing for patients with cancer, and the recent increase in stage I diagnoses is highly associated with this change.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 141-150
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change
PURPOSE: As the complexity and need for cancer care services continue to grow, time to treatment initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive analyses identifying the recent changes in TTI and the important variables causing variation in TTI for all the most prevalent cancer types. METHODS: This is a retrospective, observational study using data from the National Cancer Database from 2004 to 2015. The database was queried for newly diagnosed patients with cancer stages I-IV who had TTI within 0-180 days. Stepwise linear regression models were used as a variable selection technique to identify the most significant independent variables to evaluate as predictor variables. RESULTS: The study sample included 5,615,193 patients (median age, 65; 51.5% female; 86.1% White) across 30 different cancer types (most prevalent: breast [22.1%], lung [18.8%], prostate [16.6%]). The median [IQR] TTI across all 30 cancer types was 26 [6-47] days, with an increase of 7 days from 2004 (21 [4-44]) to 2015 (28 [9-49]; P < .001). No individual cancer type decreased in TTI from 2004 to 2015. The proportion of patients diagnosed with new stage I disease increased by 52.2% from 2004 (28.4%, n = 78,732) to 2015 (43.2%, n = 256,150). All other stages decreased in percent incidence. There was a 100.0% increase in median TTI for stage I patients from 2004 to 2015 (14-28 days). Cancer stage was the most important predictor of change in TTI for 16 cancer types ( P < .001 for all 16). CONCLUSION: TTI is increasing for patients with cancer, and the recent increase in stage I diagnoses is highly associated with this change.
- Open Access
- 12 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6804
Use of Intravascular Micro-Axial Left Ventricular Assist Devices as a Bridging Strategy for Cardiogenic Shock: Mid-Term Outcomes
Objectives: Patients in cardiogenic shock (CS) may be successfully bridged using intravascular micro-axial left ventricular assist devices (M-LVADs) for recovery or determination of definitive therapy. Methods: One hundred and seven CS patients implanted with M-LVADs from January 2020 to May 2024 were divided into four groups; group-1: 34 patients (transplant); group-2: 25 patients (LVAD); group-3: 42 patients (postcardiotomy CS (PCCS)); group-4: 6 patients (decision/recovery but excluded from analysis). Multivariable logistic regression and Multivariable Coxregression models identified predictors of early -hospital and late mortality, and Odds ratios (ORs) and hazard ratios (HRs) with p < 0.05, respectively, were considered statistically significant. SPSS 29.0 and Python 3.11.1. were used for analyses. Results: Complications included device-malfunction (6%), gastrointestinal bleed (9%), long-term hemodialysis (21%), axillary hematoma requiring re-exploration (10%), heparin-induced thrombocytopenia (4%) requiring heparin therapy cessation/initiation of argatroban infusion, and non-fatal stroke (11%). Early hospital mortality included 13 patients: 2 in group-1, 1 in group-2, 10 in group-3 (p = 0.02). In the Logistic-Regression model, category of CS requiring an M-LVAD was significant (OR = 4.7, p = 0.05). Patients were followed for 4.5 years (mean follow-up was 23 ± 17 months), and 23 deaths occurred; group-1: 3 patients, group-2: 5 patients, and group-3: 15 patients (p = 0.019). At 4.5 years, actuarial survival was 90.7 ± 5.1% in group-1, 79.2 ± 8.3% in group-2, 62.8 ± 7.7% in group-3 (p = 0.01). In the Cox-Regression model, M-LVAD category (HR = 3.63, p = 0.04), and long-term postoperative dialysis (HR = 3.9, p = 0.002) emerged as predictors of long-term mortality. Conclusions: In cardiogenic shock, mid-term outcomes demonstrate good survival with M-LVADs as bridge to transplant/durable LVADs and reasonable survival with M-LVADs as a bridge to recovery following cardiotomy, accompanied by reduced ECMO usage, and early ambulation/rehabilitation.
- 12 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6804
Open AccessUse of Intravascular Micro-Axial Left Ventricular Assist Devices as a Bridging Strategy for Cardiogenic Shock: Mid-Term Outcomes
Objectives: Patients in cardiogenic shock (CS) may be successfully bridged using intravascular micro-axial left ventricular assist devices (M-LVADs) for recovery or determination of definitive therapy. Methods: One hundred and seven CS patients implanted with M-LVADs from January 2020 to May 2024 were divided into four groups; group-1: 34 patients (transplant); group-2: 25 patients (LVAD); group-3: 42 patients (postcardiotomy CS (PCCS)); group-4: 6 patients (decision/recovery but excluded from analysis). Multivariable logistic regression and Multivariable Coxregression models identified predictors of early -hospital and late mortality, and Odds ratios (ORs) and hazard ratios (HRs) with p < 0.05, respectively, were considered statistically significant. SPSS 29.0 and Python 3.11.1. were used for analyses. Results: Complications included device-malfunction (6%), gastrointestinal bleed (9%), long-term hemodialysis (21%), axillary hematoma requiring re-exploration (10%), heparin-induced thrombocytopenia (4%) requiring heparin therapy cessation/initiation of argatroban infusion, and non-fatal stroke (11%). Early hospital mortality included 13 patients: 2 in group-1, 1 in group-2, 10 in group-3 (p = 0.02). In the Logistic-Regression model, category of CS requiring an M-LVAD was significant (OR = 4.7, p = 0.05). Patients were followed for 4.5 years (mean follow-up was 23 ± 17 months), and 23 deaths occurred; group-1: 3 patients, group-2: 5 patients, and group-3: 15 patients (p = 0.019). At 4.5 years, actuarial survival was 90.7 ± 5.1% in group-1, 79.2 ± 8.3% in group-2, 62.8 ± 7.7% in group-3 (p = 0.01). In the Cox-Regression model, M-LVAD category (HR = 3.63, p = 0.04), and long-term postoperative dialysis (HR = 3.9, p = 0.002) emerged as predictors of long-term mortality. Conclusions: In cardiogenic shock, mid-term outcomes demonstrate good survival with M-LVADs as bridge to transplant/durable LVADs and reasonable survival with M-LVADs as a bridge to recovery following cardiotomy, accompanied by reduced ECMO usage, and early ambulation/rehabilitation.
- Open Access
- 13 June 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1941-1949
Why partial heart transplantation could be regulated as organ transplantation
- 13 June 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1941-1949
Open AccessWhy partial heart transplantation could be regulated as organ transplantation
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S19)
Effects of comprehensive, individualized, person‐centered care on the relative risks of hospitalization and emergency department visits in community‐dwelling persons with advanced Alzheimer’s Disease in a 52‐week randomized controlled trial
Background: Rates of hospitalization are 3 times higher for community‐dwelling Alzheimer’s disease (AD) persons than non‐affected, age‐matched persons (Rudolph et al., J Am Geriatr Soc. 2010). These investigators reported that hospital outcomes were significantly worse for AD patients regarding delirium, prolonged length of stay, institutionalization and death. They concluded, “Given the frequency of hospitalization in …[AD]… patients, an intervention to prevent or shorten hospitalization would potentially save Medicare billions of dollars per year.” We conducted 28‐week, controlled, clinician‐blind, parallel group and 24‐week extension studies in which advanced AD persons were randomized to receive a comprehensive, individualized, person‐centered management program (CI‐PCM) developed by Sunnie Kenowsky and memantine or usual community care (UCC) and memantine (Reisberg…Kenowsky, Dement Geriatr Cogn Disord., 2017). Herein, we investigate the occurrence of hospitalization and emergency department visits (EDV) in the two groups at 52‐weeks.Methods: Each occurrence of death, hospitalization and EDV was documented. Investigators blind to group assignment analyzed occurrences. Any fraction of a hospital stay or EDV occurring on or between the baseline and week 52 visit days was recorded as one incident. Relative Risk Reduction (RRR) was calculated for the incidence of hospitalization and EDV.Results: 40% of UCC subjects experienced EDV, 40% were hospitalized and 10% died. Comparatively, only 10% of CI‐PCM subjects experienced EDV and 10% were hospitalized. UCC subjects were hospitalized for C. difficile infection, a fall and subsequent pelvic fracture, syncope and gastrointestinal disease. One CI‐PCM subject was hospitalized for a fall and hip fracture secondary to osteoporosis. UCC subject falls were attributed to neuropsychiatric symptoms of dementia. A CI‐PCM subject had C. difficile successfully treated by their physician. The RRR for utilization of the CI‐PCM program was 0.75 for EDV and 0.75 for hospitalizations (Tables 1&2).Conclusions: CI‐PCM subjects had a 75% decreased risk of EDV and a 75% decreased risk of hospitalization. Given the 5.8 million USA AD persons and the current high cost of hospitalization, the CI‐PCM program could potentially, significantly decrease the costs of care for AD persons, Medicare, and Medicaid while greatly increasing the AD person’s quality of life and alleviating their caregiver’s burden.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S19)
Open AccessEffects of comprehensive, individualized, person‐centered care on the relative risks of hospitalization and emergency department visits in community‐dwelling persons with advanced Alzheimer’s Disease in a 52‐week randomized controlled trial
Background: Rates of hospitalization are 3 times higher for community‐dwelling Alzheimer’s disease (AD) persons than non‐affected, age‐matched persons (Rudolph et al., J Am Geriatr Soc. 2010). These investigators reported that hospital outcomes were significantly worse for AD patients regarding delirium, prolonged length of stay, institutionalization and death. They concluded, “Given the frequency of hospitalization in …[AD]… patients, an intervention to prevent or shorten hospitalization would potentially save Medicare billions of dollars per year.” We conducted 28‐week, controlled, clinician‐blind, parallel group and 24‐week extension studies in which advanced AD persons were randomized to receive a comprehensive, individualized, person‐centered management program (CI‐PCM) developed by Sunnie Kenowsky and memantine or usual community care (UCC) and memantine (Reisberg…Kenowsky, Dement Geriatr Cogn Disord., 2017). Herein, we investigate the occurrence of hospitalization and emergency department visits (EDV) in the two groups at 52‐weeks.Methods: Each occurrence of death, hospitalization and EDV was documented. Investigators blind to group assignment analyzed occurrences. Any fraction of a hospital stay or EDV occurring on or between the baseline and week 52 visit days was recorded as one incident. Relative Risk Reduction (RRR) was calculated for the incidence of hospitalization and EDV.Results: 40% of UCC subjects experienced EDV, 40% were hospitalized and 10% died. Comparatively, only 10% of CI‐PCM subjects experienced EDV and 10% were hospitalized. UCC subjects were hospitalized for C. difficile infection, a fall and subsequent pelvic fracture, syncope and gastrointestinal disease. One CI‐PCM subject was hospitalized for a fall and hip fracture secondary to osteoporosis. UCC subject falls were attributed to neuropsychiatric symptoms of dementia. A CI‐PCM subject had C. difficile successfully treated by their physician. The RRR for utilization of the CI‐PCM program was 0.75 for EDV and 0.75 for hospitalizations (Tables 1&2).Conclusions: CI‐PCM subjects had a 75% decreased risk of EDV and a 75% decreased risk of hospitalization. Given the 5.8 million USA AD persons and the current high cost of hospitalization, the CI‐PCM program could potentially, significantly decrease the costs of care for AD persons, Medicare, and Medicaid while greatly increasing the AD person’s quality of life and alleviating their caregiver’s burden.
- 13 September 2023
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 167 (4) , 1385-1390
Attending your first academic cardiothoracic conference: Comprehensive guide for trainees and students
- 13 September 2023
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 167 (4) , 1385-1390
Attending your first academic cardiothoracic conference: Comprehensive guide for trainees and students